Compendium of Cancer Genome Aberrations

CNS5:Volunteer Assignments and Opportunities: Difference between revisions

← Older edit
VisualWikitext
m Formatted Author Names
m due date
 
(20 intermediate revisions by 4 users not shown)
Line 64: Line 64:
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]]
|Disease
|Disease
|Jieying Wu
|11/18/2025
|01/15/2026
|PENDING
|
|
|
|LS
|
|
|
|
|
|
|Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added
|Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added
Line 122: Line 122:
|
|
|
|
|PENDING
|COMPLETE
|
|
|LS
|LS
Line 174: Line 174:
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]]
|Disease
|Disease
|Layla Zhu
|<br />3/2/2026
|
|
|<br />
|PENDING
|
|
|
|
|LS
|LS
Line 185: Line 185:
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]]
|[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]]
|Disease
|Disease
|Wahab Khan
|2/8/2026
|
|
|
|PENDING
|
|
|
|
|
|
Line 199: Line 199:
|15/04/2025
|15/04/2025
|
|
|PENDING - email reminder 9/4/2025
|COMPLETE
|
|2/8/2026 (Feb 8)
|LS
|LS
|
|
Line 229: Line 229:
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]]
|[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]]
|Disease
|Disease
|Milana.Djonovic (trainee), Laveniya/Madina
|4/26/2026
|6/15/2026
|PENDING
|
|
|
|LS
|
|
|
|
|
|
|
|
Line 416: Line 416:
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]]
|[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 427: Line 427:
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]]
|[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 438: Line 438:
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]]
|[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]]
|Disease
|Disease
|
|Laveniya Satgunaseelan
|
|2/4/2026
|
|30/6/2026
|
|PENDING
|
|
|
|
Line 635: Line 635:
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]]
|Disease
|Disease
|Hannah Wollenzien
|1/11/2026
|
|
|Pending
|
|
|
|MS
|
|
|
|
|
|
|
Line 799: Line 799:
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|[[CNS5:Pineoblastoma|Pineoblastoma]]
|Disease
|Disease
|Fang Fang (trainee)+Katie Schieffer (mentor)
|11/19/2025
|6/15/2026
|Pending
|
|
|
|LS
|
|
|
|
|
|
|
|
Line 853: Line 853:
|[[CNS5:Schwannoma|Schwannoma]]
|[[CNS5:Schwannoma|Schwannoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Neurofibroma|Neurofibroma]]
|[[CNS5:Neurofibroma|Neurofibroma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Perineurioma|Perineurioma]]
|[[CNS5:Perineurioma|Perineurioma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]]
|[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]]
|[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 919: Line 919:
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 994: Line 994:
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,060: Line 1,060:
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,082: Line 1,082:
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]]
|[[CNS5:Ewing_sarcoma|Ewing sarcoma]]
|Disease
|Disease
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|
|
|
|
|
|-
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]]
|[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]]
|Disease
|Disease
|
|[[STBT5:Volunteer Assignments and Opportunities|See STBT5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,223: Line 1,223:
|[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]]
|[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]]
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|
|-
|
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]]
|
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|-
|[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]]
|[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]]
|Disease
|Disease
|
|
Line 1,243: Line 1,265:
|
|
|-
|-
|[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]]
|[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]]
|Disease
|Disease
|Jennie Thurston
|7/2/2023
|
|
|
|PENDING
|
|
|
|
|
|
|-
|[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]]
|Disease
|
|
|
|
|
|
|
|
|-
|[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]]
|Disease
|Jennie Thurston
|7/2/2023
|
|PENDING
|
|
|MS
|MS
Line 1,289: Line 1,289:
|[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]]
|[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]]
|[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Disease
|
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,333: Line 1,333:
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]]
|Disease
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]]
|Disease
|[[HAEM5:Volunteer Assignments and Opportunities|See HAEM5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
|N/A
|
|
|-
|
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
|
----
|
|
----
|
|
|
----
|
|-
|[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]]
|Disease
|
|
|
|
|
|
|
|
|-
|
====CHAPTER 11 (GERM CELL TUMOURS)====
|
----
|
----
|
----
|
|
----
----
Line 1,545: Line 1,545:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]]
Line 1,556: Line 1,556:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|[[CNS5:Schwannomatosis|Schwannomatosis]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,578: Line 1,578:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,600: Line 1,600:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
!'''Disease'''
!'''Disease'''
Line 1,615: Line 1,615:
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|[[CNS5:Cowden_syndrome|Cowden syndrome]]
|Disease
|Disease
|[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]]
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|N/A
|N/A
|N/A
|N/A
|N/A
Line 1,623: Line 1,622:
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]]
Line 1,633: Line 1,633:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]]
Line 1,644: Line 1,644:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]]
|[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Carney_complex|Carney complex]]
|[[CNS5:Carney_complex|Carney complex]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,688: Line 1,688:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]]
|[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,736: Line 1,736:
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
Line 1,754: Line 1,754:
|N/A
|N/A
|N/A
|N/A
|N/A
|
|-
|-
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]]
|Disease
|Disease
|
|[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship  status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|
|-
|-
|}
|}
Retrieved from "https://content.ccga.io/index.php/CNS5:Volunteer_Assignments_and_Opportunities"